MedWatch

Fate of Biogen’s stock rides on Alzheimer’s drug decision

For Biogen, the Food and Drug Administration’s expected decision Monday on its Alzheimer’s drug is what a JPMorgan Chase & Co. analyst called "the mother of all binary events" -- one that could send its shares veering sharply in either direction.

Photo: BRIAN SNYDER/REUTERS / X90051

For Biogen, the Food and Drug Administration’s expected decision Monday on its Alzheimer’s drug is what a JPMorgan Chase & Co. analyst called "the mother of all binary events" -- one that could send its shares veering sharply in either direction.

If regulators give the company approval to market the drug, called aducanumab, the stock could surge to as much to USD 450, according to Wall Street analysts. Or it could tumble to USD 200 if the treatment is shot down, according to Cory Kasimov, the JPMorgan analyst who follows the company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs